Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference.

Ann Oncol. 2007 Jul;18(7):1133-44. Review. Erratum in: Ann Oncol. 2007 Nov;18(11):1917.

PMID:
17675394
2.

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members.

Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.

3.
4.

Extended adjuvant chemotherapy in endocrine non-responsive disease.

Colleoni M, Munzone E.

Breast. 2013 Aug;22 Suppl 2:S161-4. doi: 10.1016/j.breast.2013.07.031. Review.

PMID:
24074780
5.

Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.

Montemurro F, Aglietta M.

Endocr Relat Cancer. 2009 Dec;16(4):1091-102. doi: 10.1677/ERC-09-0033. Epub 2009 Sep 2. Review.

6.

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2005 Oct;16(10):1569-83. Epub 2005 Sep 7.

PMID:
16148022
7.

Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.

Senn HJ, Thürlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS.

Breast. 2003 Dec;12(6):569-82. Review.

PMID:
14659136
8.

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2009 Aug;20(8):1319-29. doi: 10.1093/annonc/mdp322. Epub 2009 Jun 17.

9.

[Adjuvant chemotherapy of early stage breast cancer].

Boér K.

Orv Hetil. 2010 Feb 28;151(9):344-53. doi: 10.1556/OH.2010.28824. Review. Hungarian.

PMID:
20159750
10.

[Adjuvant chemotherapy in primary carcinoma of the breast].

Harbeck N.

Zentralbl Gynakol. 2003 Sep;125(9):322-6. Review. German.

PMID:
14569511
11.

Adjuvant chemotherapy in luminal breast cancers.

Lim E, Winer EP.

Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Review.

PMID:
22015279
12.

Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies.

Viale G, Ghioni M, Mastropasqua MG.

Curr Opin Oncol. 2010 Nov;22(6):541-6. doi: 10.1097/CCO.0b013e32833f4882. Review.

PMID:
20827197
13.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4.

14.

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Chia YH, Ellis MJ, Ma CX.

Br J Cancer. 2010 Sep 7;103(6):759-64. doi: 10.1038/sj.bjc.6605845. Epub 2010 Aug 10. Review.

15.

[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].

Vanacker H, Bally O, Kassem L, Tredan O, Heudel P, Bachelot T.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S47-52. doi: 10.1016/S0007-4551(15)31217-0. Review. French.

PMID:
26118876
16.

Endocrine therapy: is the first generation of targeted drugs the last?

Pritchard KI.

J Intern Med. 2013 Aug;274(2):144-52. doi: 10.1111/joim.12065. Review.

17.

Clinical implications of the intrinsic molecular subtypes of breast cancer.

Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M.

Breast. 2015 Nov;24 Suppl 2:S26-35. doi: 10.1016/j.breast.2015.07.008. Epub 2015 Aug 5. Review.

18.

Adjuvant endocrine treatment in premenopausal early breast cancer.

Orlando L, Fedele P, Cinefra M, Sponziello F, Calvani N, Chetrì MC, Rizzo P, D'Amico M, Schiavone P, Portaluri M, Criscuolo M, Burlizzi S, Cinieri S.

Oncology. 2009;77 Suppl 1:9-13. doi: 10.1159/000258490. Epub 2010 Feb 2. Review.

PMID:
20130426
19.

Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?

Forbes JF, Gradishar WJ, Ravdin PM.

Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S37-44; discussion S57-9. Review.

PMID:
12353822
20.

Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?

Biganzoli L, Claudino WM, Pestrin M, Pozzessere D, Di Leo A.

Crit Rev Oncol Hematol. 2007 Apr;62(1):1-8. Epub 2007 Feb 21. Review.

PMID:
17317203

Supplemental Content

Support Center